Trek Medical

Trek Therapeutics is a private biopharmaceutical company and public benefit corporation focused on developing affordable and accessible treatments for infectious diseases, with a primary emphasis on Hepatitis C (HCV). The company's business model aims to disrupt the pharmaceutical market by offering highly effective antiviral regimens at significantly lower prices than current market standards, particularly targeting middle-income countries and underserved populations. Trek's portfolio consists of acquired clinical-stage assets, including protease, NS5A, and polymerase inhibitors, which it combines into all-oral, interferon-free regimens. Led by industry veterans with extensive experience in antiviral drug development, the company seeks to demonstrate that a profitable for-profit model can coexist with a mission to expand global access to life-saving medicines.